Dr. Stephen D. Wiviott is a graduate of University of Pennsylvania (Mathematics, Magna Cum Laude) in 1990 and Harvard Medical School (Honors) in 1996. He served as a Medical House Officer and Chief Medical Resident at Brigham and Women’s Hospital. Following his medical residency training, he served as a Cardiology Fellow at Johns Hopkins Hospital and as a Cardiovascular Research Fellow with the TIMI Study Group with the Cardiovascular Division of Brigham and Women’s Hospital. After completion of his training he has joined the faculty of the Cardiovascular Division of Brigham and Women’s Hospital and serves as Associate Professor of Medicine at Harvard Medical School, and a Senior Investigator with the TIMI Study Group.
As an investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group he has played important roles in the planning, implementation and interpretation of several multicenter, national and international clinical trials. He has played leadership roles in the JUMBO – TIMI 26 trial and the TRITON – TIMI 38 trial the major phase 2 and phase 3 trials of prasugrel a third generation thienopyridine. He was the Principal Investigator of PRINCIPLE – TIMI 44, a study comparing high-dose clopidogrel with prasugrel in patients undergoing PCI and of the TIMI 38 Coronary Stent Registry, an ongoing international registry of the long-term outcomes of patients receiving different types of intracoronary stents for acute coronary syndromes. He was a lead physician for the LANCELOT program evaluating the novel antiplatelet agent atopaxar, a PAR-1 antagonist.
In addition, Dr Wiviott has played major roles in the design and implementation of several trials of metabolic therapies (lipid lowering, weight loss and anti-diabetic therapies) in patients with acute coronary syndromes or chronic atherosclerotic disease. These trials include trials of intensive statin therapy PROVE IT – TIMI 22, A to Z TIMI 25 in ACS, and of the cholesteryl esterase transfer protein (CETP) inhibitor anacetrapib in the ongoing REVEAL – HPS 3 – TIMI 55. He is world-wide co-prinicipal investigator for the DECLARE – TIMI 58 trial, the largest clinical outcomes study of an SGLT-2 inhibitor in patients with type 2 diabetes and CAMELLIA – TIMI 61, a cardiovascular outcomes study of the weight loss agent lorcaserin.
Dr. Wiviott serves as the physician chairman of the TIMI Clinical Events Committee, a leading event adjudication group in cardiovascular disease. In this role, he has served as chairman of major studies ranging from 100s to more than 10,000 endpoints evaluated – in CV disease, neurology, oncology, hepatology, and endocrinology – supporting major publications and registration of new medications by regulatory agencies world-wide. As an expert in event adjudication, he has served as leader for major projects to define and evaluate cardiovascular events in clinical-trials in collaboration with academics, industry and US regulators.
Dr. Wiviott is an author of more than one hundred and fifty peer-reviewed publications in major medical and cardiovascular journals including the New England Journal of Medicine, JAMA, Lancet, Circulation, JACC and the European Heart Journal as well as multiple chapters in major cardiovascular textbooks including Braunwald’s Heart Disease. He was named in 2014 by Thompson Reuters one of “The World’s Most Influential Scientific Minds” in Medicine based on impact of his publications. Dr. Wiviott has delivered local, national and international lectures in the field of acute coronary syndromes, platelet biology, established and novel antiplatelet agents, metabolic agents, and anticoagulants. Areas of clinical and research interest include acute coronary syndromes, platelet biology, platelet inhibitors, and metabolic therapies.